U.S. approves Acadia drug for Parkinson's disease-linked psychosis
April 29, 2016 at 17:38 PM EDT
April 29 (Reuters) - Acadia Pharmaceuticals Inc's drug for psychosis linked to Parkinson's disease was approved by the U.S. Food and Drug Administration on Friday, becoming the first ever treatment to get a U.S. nod for the condition.
